Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

被引：23
|
作者：
Daver, Naval
Altman, Jessica K.
Maly, Joseph
Levis, Mark
Ritchie, Ellen
Litzow, Mark
McCloskey, James K.
Smith, Catherine C.
Schiller, Gary J.
Bradley, Terrence
Tiu, Ramon V.
Hong, Wan-Jen
Tong, Bo
Qin, Qin
Dilley, Kimberley
Perl, Alexander E.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139705
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy
    Ong, Faustine
    Short, Nicholas
    Daver, Naval
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Yilmaz, Musa
    Alvarado, Yesid
    Vaughan, Kenneth
    Pierce, Sherry A.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    BLOOD, 2022, 140 : 9029 - 9031
  • [42] Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia
    McMahon, Christine M.
    Canaani, Jonathan
    Rea, Bryan
    Sargent, Rachel Lynn
    Morrissette, Jennifer J. D.
    Lieberman, David B.
    Watt, Christopher
    Schwartz, Gregory W.
    Faryabi, Robert B.
    Ferng, Timothy T.
    Shah, Neil P.
    Smith, Catherine C.
    Carroll, Martin
    Perl, Alexander E.
    BLOOD, 2017, 130
  • [43] Long-term survivors and gilteritinib safety beyond 1 year in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia: ADMIRAL trial follow-up
    Perl, Alexander E.
    Martinelli, Giovanni
    Neubauer, Andreas
    Berman, Ellin
    Baer, Maria R.
    Larson, Richard A.
    Fathi, Amir T.
    Yokoyama, Hisayuki
    Hosono, Naoko
    Hasabou, Nahla
    Lu, Qiaoyang
    Tiu, Ramon V.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 3 - 4
  • [44] Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3-Mutated AML: Results of a Phase 1 Study
    Altman, Jessica K.
    Bhatnagar, Bhavana
    Abedin, Sameem
    Przespolewski, Amanda
    Patel, Prapti A.
    Schiller, Gary J.
    Gill, Stanley
    Patel, Dhruva
    Fan, Linyi
    Tiu, Ramon V.
    Strickland, Stephen A.
    BLOOD, 2021, 138
  • [45] Pegcrisantaspase in Combination with Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: A Phase 1 Study
    Niyongere, Sandrine
    Duong, Vu H.
    Bollino, Dominique R.
    Lapidus, Rena G.
    Strovel, Erin T.
    Zarrabi, Jinoos
    Bah, Osman Mohamed
    Philip, Sunita
    Kflu, Veronica
    Baer, Maria R.
    Emadi, Ashkan
    BLOOD, 2021, 138
  • [46] Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
    Maiti, Abhishek
    DiNardo, Courtney D.
    Daver, Naval G.
    Rausch, Caitlin R.
    Ravandi, Farhad
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Borthakur, Gautam
    Bose, Prithviraj
    Issa, Ghayas C.
    Short, Nicholas J.
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Jain, Nitin
    Ohanian, Maro
    Takahashi, Koichi
    Thompson, Philip A.
    Loghavi, Sanam
    Montalbano, Kathryn S.
    Pierce, Sherry
    Wierda, William G.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD CANCER JOURNAL, 2021, 11 (02)
  • [47] Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
    Abhishek Maiti
    Courtney D. DiNardo
    Naval G. Daver
    Caitlin R. Rausch
    Farhad Ravandi
    Tapan M. Kadia
    Naveen Pemmaraju
    Gautam Borthakur
    Prithviraj Bose
    Ghayas C. Issa
    Nicholas J. Short
    Musa Yilmaz
    Guillermo Montalban-Bravo
    Alessandra Ferrajoli
    Elias J. Jabbour
    Nitin Jain
    Maro Ohanian
    Koichi Takahashi
    Philip A. Thompson
    Sanam Loghavi
    Kathryn S. Montalbano
    Sherry Pierce
    William G. Wierda
    Hagop M. Kantarjian
    Marina Y. Konopleva
    Blood Cancer Journal, 11
  • [48] Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia:Updated Results from a Phase I Study
    Jin, Jie
    Wang, Huafeng
    Yu, Wen-Juan
    Ge, Zheng
    Wei, Xudong
    Li, Yuhua
    Jiang, Zhongxing
    Li, Yiqing
    Du, Xin
    Yang, Linhua
    Lin, Lie
    Wang, Jishi
    Yao, Yazhou
    Hu, Xiaoping
    Lan, Jianping
    Deng, Xiuzhi
    Chen, Tong
    Feng, Xianqi
    Li, Dengju
    Hou, Ming
    Fu, Rong
    Huang, Siyong
    Wang, Jingbo
    Du, Xin
    Yang, Hui
    Yang, Haiping
    Jiang, Yingzhi
    Wang, Zhijie
    Li, Deng
    Liu, Bing
    Kang, Ning
    Zhuang, Yulei
    Zhang, Yingjun
    BLOOD, 2023, 142
  • [49] Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
    Chew, Serena
    Mackey, Melissa C.
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [50] Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
    Numan, Yazan
    Abdel Rahman, Zaid
    Grenet, Justin
    Boisclair, Stephanie
    Bewersdorf, Jan Philipp
    Collins, Cailin
    Barth, Dylan
    Fraga, Martina
    Bixby, Dale L.
    Zeidan, Amer M.
    Yilmaz, Musa
    Desai, Pankil
    Mannis, Gabriel
    Deutsch, Yehuda E.
    Abaza, Yasmin
    Dinner, Shira
    Frankfurt, Olga
    Litzow, Mark
    Al-Kali, Aref
    Foran, James M.
    Sproat, Lisa Z.
    Jovanovic, Borko
    Daver, Naval
    Perl, Alexander E.
    Altman, Jessica K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : 322 - 328
12345